Tagomics
Tagomics is a UK-based company developing a proprietary multiomic platform that integrates genetic, epigenetic, and fragmentomic features to unlock disease-associated biomarkers from various biological sources. Their technology combines advanced bioinformatics and machine learning to provide unique biological insights, enabling high-throughput, economical, and automatable multiomic disease profiling. Tagomics focuses on transforming disease diagnosis, particularly in oncology and other clinical applications, by offering enhanced sensitivity, specificity, and deeper clinical insights. The company collaborates with biopharma and clinical research institutions to develop genomics-based diagnostics and precision medicines, with notable partnerships such as a co-marketing agreement with Agilent Technologies. They have received significant funding, including a £860k Innovate UK Biomedical Catalyst grant for colorectal cancer detection, and have raised £6.7m in funding rounds, positioning them as an innovative player in the genomics and diagnostics market.
Tagomics
Tagomics is a UK-based company developing a proprietary multiomic platform that integrates genetic, epigenetic, and fragmentomic features to unlock disease-associated biomarkers from various biological sources. Their technology combines advanced bioinformatics and machine learning to provide unique biological insights, enabling high-throughput, economical, and automatable multiomic disease profiling. Tagomics focuses on transforming disease diagnosis, particularly in oncology and other clinical applications, by offering enhanced sensitivity, specificity, and deeper clinical insights. The company collaborates with biopharma and clinical research institutions to develop genomics-based diagnostics and precision medicines, with notable partnerships such as a co-marketing agreement with Agilent Technologies. They have received significant funding, including a £860k Innovate UK Biomedical Catalyst grant for colorectal cancer detection, and have raised £6.7m in funding rounds, positioning them as an innovative player in the genomics and diagnostics market.
